Trial Profile
Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms RAPSON
- 24 May 2023 Planned End Date changed from 1 Aug 2022 to 1 Jul 2025.
- 24 May 2023 Planned primary completion date changed from 1 Aug 2021 to 1 Jul 2025.
- 27 Sep 2018 New trial record